Follicum re-starts phase II study with FOL-005 for stimulation of hair growth and expands the number of study centres

Follicum AB ("Follicum" or the "company") today announced that the clinical Phase IIa study with a cream-like formulation of  FOL-005 will re-start, following a pause due to the Covid-19 pandemic. To increase the recruitment rate, a third study centre has been contracted. The study comprises approximately 200 male patients with hair loss who are treated daily for four months with the newly developed formulation of FOL-005 or placebo. The study is being conducted at the Clinical Research Center for Hair and Skin Science ("CRC") in Berlin, proDERM in Hamburg, and the new center, CentroDerm® in